Decoy Therapeutics Nominates Moderna VP Who Delivered 50M COVID-19 Doses to Board
DCOY•Decoy Therapeutics has nominated Patricia Gauthier, Senior VP at Moderna overseeing 500 employees across Australia, Canada and the UK, as a Class II director to be voted on July 14, 2026. Gauthier brings experience building Moderna Canada from inception, delivering 50M COVID-19 doses and securing a national biomanufacturing partnership.
1. Nomination Details
Decoy Therapeutics has nominated Patricia Gauthier, MBA, LL.B., as a Class II director, with her election to be voted on at the Annual Meeting of Stockholders on July 14, 2026, succeeding long-serving board member David Arthur.
2. Biopharma Leadership Background
Since 2025, Gauthier has served as Senior Vice President and Regional Head for Australia, Canada and the UK at Moderna, leading strategy, operations and a 500-member team. She previously built Moderna Canada from inception, delivered over 50 million COVID-19 vaccine doses and secured a landmark biomanufacturing partnership with the Government of Canada, and held senior leadership roles at GSK.
3. Expected Strategic Contributions
Decoy’s CEO anticipates Gauthier’s expertise in building commercial organizations, securing national health security partnerships and managing cross-border medicine delivery will accelerate advancement of Designable Multi-Antiviral (D-MAV) candidates toward clinical development and broaden their real-world impact.
